SLDB Solid Bio: Net earnings per share growth forecast for next year
Solid Biosciences Inc. (SLDB) management is strictly limiting expenses, focusing on the advancement of SGT-003. The projected change in earnings per share for the coming year visualizes these expectations, where the 4.60 level captures the current state. Growth is supported by unique therapy delivery vectors, while the production capacities of external partners ensure high laboratory utilization for the development of genetic medicines.
SLDB (solidbio.com): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- company stock capitalization data:
- company book value details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Solid Biosciences Inc.|SLDB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Solid Biosciences|SLDB - Company Cumulative Debt|Debt to Book Capitalization Ratio Solid Biosciences|SLDB - Company Long-Term Indebtedness|Company Short-Term Debts Solid Biosciences|Quick Ratio solidbio.com
- net income and valuation ratios data:
SLDB - Company Net Income|Expected Profit Solid Biosciences Inc.|SLDB - Business Payback Period|Projected Price to Earnings Solid Biosciences Inc.|SLDB - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Solid Biosciences|SLDB - Operating income before deduction of amortization|Earnings per share for the last twelve months Solid Biosciences|SLDB - Earnings per share for the last 12 months|Quarterly EPS earnings growth solidbio.com|SLDB - Net earnings per share growth this year|Expected earnings per share growth for next year Solid Biosciences Inc.
- revenue and sales details:
Fundamental company analysis:SLDB, Solid Bio
Assessing the financial stability of Solid Biosciences Inc. (SLDB) requires an analysis of future profitability. This indicator measures the expected earnings per share (EPS) dynamics, reflecting the market consensus regarding revenue growth rates. By analyzing the consensus forecast for forward-looking EPS growth rates, an investor can separate fundamental trends from market noise. For the biotechnology sector, this metric confirms the viability of the patent portfolio prior to the commercialization of gene therapy.
Competing companies
TEM (Tempus AI, Inc) - Earnings growth forecast for next year|Qiagen Corp (QGEN) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Ionis Pharmaceuticals (IONS)|RGEN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Avidity Biosciences, Inc. RNA|Consensus forecast of earnings per share growth for next year CRISPR Therapeutics Inc (CRSP)|Sema4 - Earnings growth forecast for next year|Ultragenyx Corp (RARE) - Expected earnings per share growth for next year|BEAM: Earnings growth forecast for next year|SRPT - Consensus forecast of earnings per share growth for next year|TWST (Twist Bioscience, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year 10x Genomics Inc TXG|Net earnings per share growth forecast for next year Intellia (NTLA)|Stoke Corp - Projected earnings per share growth rate for next year|Earnings growth forecast for next year BLFS (BioLife Solutions, Inc.)|WVE - Expected earnings per share growth for next year|Maze Therapeutics - Earnings growth forecast for next year|Expected net earnings per share growth next year Sionna Therapeutics, Inc.|Prime Medicine Corp (PRME) - Net earnings per share growth forecast for next year|TSHA - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year QURE|MGTX: Expected earnings per share trend next year|Earnings growth forecast for next year RGNX|Consensus forecast of earnings per share growth for next year Ocugen Inc|Net earnings per share growth forecast for next year Pacific Biosciences of California PACB|BNTC: Projected earnings per share growth rate for next year|Design Therapeutics - Earnings growth forecast for next year|rocketpharma.com (RCKT) - Expected earnings per share growth for next year|FDMT (4D Molecular Therapeutics, Inc.) - Expected earnings per share growth for next year|LXEO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Korro Bio Inc.|Editas Corp (EDIT) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Silence Therapeutics (SLN)|Net earnings per share growth forecast for next year PRQR (proqr.com)|Earnings growth forecast for next year CDXS (Codexis)|SGMO: Projected earnings per share growth rate for next year|Nautilus Biotechnology Inc - Earnings growth forecast for next year|MGX: Net earnings per share growth forecast for next year|DTIL: Earnings growth forecast for next year|Projected earnings per share growth rate for next year GBIO|Net earnings per share growth forecast for next year Boundless Bio|Projected earnings per share growth rate for next year XCUR (Exicure Corp)|Earnings growth forecast for next year IMNN|Earnings growth forecast for next year phiopharma.com (PHIO)|Net earnings per share growth forecast for next year Mustang Bio MBIO|Consensus forecast of earnings per share growth for next year TransCode Therapeutics Inc. (RNAZ)|BNGO - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Applied DNA Sciences Inc|Bluebird Bio (BLUE) - Net earnings per share growth forecast for next year|IPA (ImmunoPrecise Antibodies Ltd.) - Net earnings per share growth forecast for next year|OMGA (Omega Therapeutics) - Earnings growth forecast for next year|singulargenomics.com (OMIC) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year RGLS|Syros Pharmaceuticals Inc. - Projected earnings per share growth rate for next year|Codex DNA - Expected earnings per share growth for next year|Expected earnings per share trend next year TCON|Unity Biotechnology - Earnings growth forecast for next year
